DESIFOR-EXPAND (MHIF)

NCT06804980

Status	RECRUITING
Phase	Phase 4
Sponsor	Minneapolis Heart Institute Foundation
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (2)

- Adult patients (e 21 years old) with a prior history of statin intolerance. Statin intolerance is defined by discontinuation of at least 2 different statin medications due to possible side effects. Patients can participate in the trial while on other lipid-lowering agents, such as ezetimibe and PSCK9 inhibitors, as long as the patient has been on the other lipid lowering therapy and tolerating it well for at least 1 month. For individuals with established ASCVD or multiple ASCVD risk factors, initiation of other lipid lowering therapy prior to participation in DESIFOR is encouraged.
- \. At least 30 days since discontinued use of a statin

Exclusion (3)

- Women who are pregnant, nursing or attempting to become pregnant
- Individuals who experienced severe reactions in the past, including rhabdomyolysis, severe myositis, anaphylaxis
- Individuals who are not otherwise clinically indicated to take rosuvastatin 20 mg

Locations (1 total)

Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States